Patent ID: 11951115
Assignee: UNITY BIOTECHNOLOGY, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 26:
27. The method of claim 14, wherein the patient demonstrates at least a 0.10 mm2 reduction of ocular avascular area over baseline, or at least a 0.20 mm2 reduction of ocular avascular area over baseline, or at least a 0.30 mm2 reduction of ocular avascular area over baseline, or at least a 0.40 mm2 reduction of ocular avascular area over baseline, or at least a 0.50 mm2 reduction of ocular avascular area over baseline, or at least a 0.60 mm2 reduction of ocular avascular area over baseline, or at least a 0.70 mm2 reduction of ocular avascular area over baseline, or at least a 0.80 mm2 reduction of ocular avascular area over baseline, or at least a 0.90 mm2 reduction of ocular avascular area over baseline, or at least a 1.0 mm2 reduction of ocular avascular area over baseline, all as measured by fluorescence angiography (FA) or optical coherence tomography angiography (OCT-A).